Pune-based Emcure Pharmaceuticals is scouting for land in Gujarat to set up a formulations plant here, state government sources indicated.
The privately held company which is into manufacturing both active pharmaceutical ingredients (APIs) and pharmaceutical formulations, currently has three formulations plants and one API manufacturing plant in Pune.
"The company officials visited Gujarat to scout for location around two weeks back and plan to invest around Rs 150 crore to set up a formulation plant here," informed a senior state government official close to development. The company officials could not be reached for a comment.
Emcure is one of the largest contract manufacturers of tablets, capsules, liquids, ointments and creams in India and manufactures the key brands for some of the largest MNCs in India, the company website noted.
It forayed into supplying the regulated markets with the setting up of a solid dosages facility at Hinjwadi.
The Hinjwadi manufacturing facility has approvals from both the UK MHRA and MCC South Africa, while the USFDA certification was received recently for the solid dosages plant.
The company also has a facility for manufacturing liquid injectables, while the small volume parenterals facility has independent lines for filling pre-filled syringes, vials and ampoules. This plant has been set up as per standards and guidelines laid down by US FDA, the website noted adding that "to cater to the demand of domestic market and emerging markets a new state of the art facility at Bari - Brahmana Jammu, India was created in 2009. This facility manufactures both solid and liquid orals."
Emcure has set up research and development centers for both API and formulations at Pimpri, Bhosari and Hinjwadi in Pune. It has operations in India, USA, Latin America, Middle East, Africa and other emerging markets.
In the last few months, a slew of domestic and global pharmaceutical companies have shown interest in coming to Gujarat, which accounts for almost one-third of the country's pharmaceutical production.
Abbott India, a subsidiary of Illinois head-quartered Abbott Laboratories is all set start commercial production at its upcoming facility at Jhagadia this year where it plans to make nutraceutical products.
Meanwhile, Teva and Proctor & Gamble (P&G) joint venture that would be making the Vicks range of products from P&G stable at Sanand, has started work on the first phase of the project.
Associated Capsules Private Limited (ACPL), one of the largest producers of pharmaceutical empty hard gelatine capsules in the world, is also planning to set up a plant in Bharuch for the same.